With the deeper understanding of the pathological mechanisms of periodontitis, new therapeutic strategies have been proposed and applied, among which AMY-101 (C3 inhibitor), as a novel complement inhibitor targeting its complement component (C3), has attracted much attention in recent years for its application in the treatment of periodontitis (5). Here, C3 is linked to periodontitis.